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Abstract
Background: Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLB) and Parkinson’s disease
dementia (PDD), is characterised by marked deficits within the cholinergic system which are more severe than in
Alzheimer’s disease (AD) and are mainly caused by degeneration of the nucleus basalis of Meynert (NBM) whose
widespread cholinergic projections provide the main source of cortical cholinergic innervation. EEG alpha reactivity,
which refers to the reduction in alpha power over occipital electrodes upon opening the eyes, has been suggested
as a potential marker of cholinergic system integrity.
Methods: Eyes-open and eyes-closed resting state EEG data were recorded from 41 LBD patients (including 24
patients with DLB and 17 with PDD), 21 patients with AD, and 40 age-matched healthy controls. Alpha reactivity
was calculated as the relative reduction in alpha power over occipital electrodes when opening the eyes. Structural
MRI data were used to assess volumetric changes within the NBM using a probabilistic anatomical map.
Results: Alpha reactivity was reduced in AD and LBD patients compared to controls with a significantly greater
reduction in LBD compared to AD. Reduced alpha reactivity was associated with smaller volumes of the NBM
across all groups (ρ = 0.42, pFDR = 0.0001) and in the PDD group specifically (ρ = 0.66, pFDR = 0.01).
Conclusions: We demonstrate that LBD patients show an impairment in alpha reactivity upon opening the eyes
which distinguishes this form of dementia from AD. Furthermore, our results suggest that reduced alpha reactivity
might be related to a loss of cholinergic drive from the NBM, specifically in PDD.
Keywords: Resting state EEG, Structural MRI, Dementia with Lewy bodies, Parkinson’s disease dementia, Nucleus
basalis of Meynert
Background
Lewy body dementia (LBD) includes dementia with
Lewy bodies (DLB) and Parkinson’s disease dementia
(PDD) and is the second most common form of neuro-
degenerative dementia after Alzheimer’s disease (AD)
[1]. LBD is characterised by Parkinsonism, fluctuating
cognition, rapid eye movement sleep behaviour disorder,
and visual hallucinations [2].
Both LBD and AD patients show marked cholinergic
deficits which are more severe in LBD compared to AD
and occur earlier in the course of the disease [3, 4]. In
LBD, the cortical cholinergic deficit is mainly caused by
degeneration of cholinergic nuclei within the basal fore-
brain [5]. The substantia innominata forms part of the
basal forebrain and contains the nucleus basalis of
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Meynert (NBM) whose cholinergic neurons have wide-
spread connections to the entire cortex providing the
main source of cortical cholinergic innervation [6]. Sev-
eral studies have identified structural abnormalities
within the substantia innominata in LBD which are
more pronounced than in AD [7, 8].
Cholinergic deficits are believed to be one of the major
causes of cognitive dysfunction in dementia. In Parkin-
son’s disease, loss of cholinergic neurons in the NBM
and cortical cholinergic dysfunction are related to the
development of dementia [9, 10] and NBM degeneration
is predictive of future cognitive decline [11]. In AD pa-
tients, NBM volume is correlated with overall cognitive
performance [12].
In particular, cognitive fluctuations, which are a com-
mon symptom of both DLB and PDD, have been linked
to imbalances within the cholinergic system [13]. Struc-
tural abnormalities in the substantia innominata have
been shown to be related to the severity of cognitive
fluctuations in DLB [7], and cholinesterase inhibitors
can ameliorate this clinical symptom [14].
Previous studies have found an association between
cholinergic innervation from subcortical structures and
cortical neural signals as measured by EEG. In resting,
eyes-closed conditions, a prominent rhythm in the alpha
frequency range can be observed in the EEG which re-
sults from the synchronous firing of many cortical neu-
rons summing to form large-amplitude signals [15]. In
the healthy brain, opening of the eyes leads to a marked
attenuation of alpha power due to desynchronization of
neuronal activity [15, 16]. The magnitude of this reduc-
tion in alpha power from eyes closed to eyes open—
termed alpha reactivity—has been suggested as a marker
of cholinergic system integrity [17, 18].
Studies in AD found a decrease in alpha reactivity
compared to healthy controls [19, 20]. This reduced
alpha reactivity in AD has been shown to be related to
the severity of cognitive impairment and was also ob-
served in individuals with amnestic mild cognitive im-
pairment (MCI) who are at an increased risk of
developing AD, suggesting that changes in alpha reactiv-
ity might occur early in the course of the disease [20].
Franciotti et al. [21] investigated differences in alpha
reactivity between AD and DLB patients using magne-
tencephalography (MEG). While they observed a de-
crease in alpha reactivity in the dementia groups
compared to controls, they did not find differences be-
tween AD and DLB which might be due to the small
sample size including only seven DLB patients [21].
Similarly, Bosboom et al. [22] found a reduction in alpha
reactivity in PDD patients compared to controls using
MEG.
However, no previous study has investigated differ-
ences in alpha reactivity between AD and LBD in a
larger cohort, and how changes in alpha reactivity relate
to cholinergic system integrity in these patients.
The first aim of the present study was therefore to as-
sess alpha reactivity in a cohort of LBD patients com-
pared to AD patients with similar levels of cognitive
impairment and to healthy age-matched controls. We
hypothesised that alpha reactivity would be reduced in
the dementia groups with a more pronounced decrease
in LBD compared to AD given the more severe choliner-
gic deficit in the former group [3]. The second aim was
to investigate the association between changes in alpha
reactivity and volumetric changes within the cholinergic
system in LBD and AD. Here, we hypothesised that a re-
duction in alpha reactivity would be related to reduc-
tions in NBM volume in the dementia groups. Based on
evidence from previous studies suggesting a link be-
tween cognitive fluctuations and disturbances within the
cholinergic system [7], we also hypothesised that a
reduction in alpha reactivity would be related to more
severe cognitive fluctuations in LBD.
Methods
Participants
This study involved 102 participants over 60 years of
age. Forty-one were diagnosed with probable LBD (24
DLB and 17 PDD), 21 were diagnosed with probable
AD, and 40 were healthy controls of similar age with no
history of psychiatric or neurological illness. Patients
were recruited from the local community-dwelling
population who had been referred to old-age psychiatry
and neurology services. The study was approved by the
local ethics committee, and written informed consent
was obtained from all participants. Dementia diagnoses
were performed independently by two experienced clini-
cians in alignment with consensus criteria for probable
DLB [2], PDD [23], and AD [24]. Patients who were tak-
ing dopaminergic medication were assessed in the “ON”
motor state.
All participants underwent detailed neurological and
neuropsychiatric testing including the Mini-Mental State
Examination (MMSE) as a measure of global cognition,
the Unified Parkinson’s Disease Rating Scale part III for
the assessment of Parkinsonian motor problems, and the
Neuropsychiatric Inventory (NPI) hallucinations sub-
scale which was specifically focussed on the occurrence
of visual hallucinations. For the assessment of cognitive
fluctuations, we used the Mayo Fluctuation Scale [25].
EEG acquisition and pre-processing
Resting state EEG recordings were acquired from all par-
ticipants using Waveguard caps (ANT Neuro, The
Netherlands) comprising 128 sintered Ag/AgCl elec-
trodes that were placed according to the 10–5 system.
Participants were seated during the recording and
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instructed to remain awake. Electrode impedance was
kept below 5 kΩ, and continuous EEG data were re-
corded at a sampling frequency of 1024 Hz. One hun-
dred fifty seconds of eyes-closed and 150 s of eyes-open
data were recorded from each participant. Participants
were supervised by the EEG technician during the re-
cording to monitor adherence to the protocol (i.e. eyes
open vs eyes closed). The ground electrode was attached
to the right clavicle, and all EEG channels were refer-
enced to Fz during recording.
Pre-processing of eyes-closed and eyes-open EEG data
was performed blinded to group membership, and the
methods applied were the same as described in [26].
Briefly, data were filtered between 0.3 and 54 Hz using a
second order Butterworth filter, noisy EEG segments
and noisy EEG channels were deleted, and independent
component analysis was used for artefact removal. The
deleted channels were then replaced using spherical
spline interpolation, and data were recomputed against
the average reference and split into non-overlapping
epochs of 2 s. For each participant, the first 45 2-s long
artefact-free epochs from the eyes-closed data and the
first 45 2-s long artefact-free epochs from the eyes-open
data were selected for further analysis.
Alpha reactivity analysis
EEG data from three occipital electrodes (O1, O2, and
Oz) were selected for the alpha reactivity analysis (Fig.
2a) [17]. For each electrode separately, the power spec-
tral density (PSD) was estimated using Bartlett’s method
with a frequency resolution of 0.25 Hz and a Hamming
window. The resulting PSD for the three electrodes was
averaged across the 45 epochs and across the three elec-
trodes for each condition separately (eyes open and eyes
closed). Alpha reactivity was then calculated according
to the following formula [17]:
alpha reactivity ¼ alpha power eyes closed−alpha power eyes open
alpha power eyes closed
where alpha power was computed as the relative power
within a frequency bin around the individual alpha peak
frequency ± 2 Hz. Individual alpha peak frequencies were
calculated by finding the peak in the PSD in the ex-
tended alpha frequency band from 4 to 14 Hz [20] using
the eyes-closed data. Individual alpha peak frequencies
were used instead of the standard alpha frequency band
to account for a shift of the alpha peak to slower
frequencies in AD and LBD [26, 27].
MRI acquisition and pre-processing
There were 40 healthy controls, 19 AD, 20 DLB, and 16
PDD participants from the alpha reactivity analysis with
structural MRI data. MR images were acquired on a 3-T
Philips Intera Achieva scanner with a magnetization
prepared rapid gradient echo (MPRAGE) sequence, sa-
gittal acquisition, echo time 4.6 ms, repetition time 8.3
ms, inversion time 1250 ms, flip angle = 8°, SENSE fac-
tor = 2, and in-plane field of view 240 × 240mm2 with
slice thickness 1.0 mm, yielding a voxel size of 1.0 ×
1.0 × 1.0 mm3.
Pre-processing of MR images was performed in
SPM12 (http://www.fil.ion.ucl.ac.uk/spm/). First, images
were segmented into grey matter, white matter, and
cerebrospinal fluid. The segmented grey matter images
were then coregistered and normalised to MNI space
using SPM’s DARTEL algorithm [28] and modulated. As
a final step, images were smoothed with a 4-mm full
width at half maximum Gaussian kernel.
Analysis of nucleus basalis of Meynert volumes
The NBM was identified using a probabilistic anatomical
map from the SPM Anatomy Toolbox [29] which was
created using microscopic delineations of ten post-
mortem human brains [30]. The NBM forms part of the
basal forebrain which consists of cholinergic cells that
can be histologically defined as Ch1–Ch6 where Ch4
corresponds to the NBM [31]. A region of interest mask
for the NBM was created using the SPM Anatomy Tool-
box (see Fig. 1). NBM volume was averaged across the
right and left hemispheres. For each participant, grey
matter volume within the mask was calculated. Add-
itionally, the total intracranial volume was calculated in
SPM to normalise NBM volume.
Statistics
Individual alpha peak frequency, alpha reactivity, and
alpha power (eyes open and eyes closed) were compared
between the groups using univariate ANOVAs or
Kruskal-Wallis ANOVAs depending on whether the data
were normally distributed. Post hoc tests were
Bonferroni-corrected for multiple comparisons. The
same analysis was used to compare NBM volume (cor-
rected for total intracranial volume) between groups.
Correlations between alpha reactivity and NBM volume
were computed using Spearman’s correlations, across
all groups and separately in each clinical group.
Additionally, Spearman’s correlations between alpha
reactivity and NBM volumes and clinical scores were
tested for the Mayo Fluctuation Scale (total score and cog-
nitive subscore) and for the MMSE as a measure of overall
cognition, in each dementia group separately. False
discovery rate (FDR) correction was used to correct
correlation p values for multiple comparisons.
To assess the influence of dopaminergic medication,
the EEG measures were compared between those LBD
patients taking dopaminergic medication (N = 28) and
those not taking dopaminergic medication (N = 13)
using two-sample t tests. Additionally, we assessed
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Spearman’s correlations between levodopa equivalent
daily dose (LEDD) [32] and the EEG measures in those
LBD patients who were on dopaminergic medication.
Results
Demographics
All three groups were similar in age (see Table 1).
Although not statistically significant, there was a ten-
dency for group differences in terms of gender, i.e. LBD
patients were predominantly male whereas gender was
more balanced in the AD group. To make sure that
results were not influenced by these gender differences
between groups, all group comparisons were repeated
including gender as a covariate. The AD and LBD
groups did not differ significantly with respect to overall
cognition (MMSE) and dementia duration. As expected,
the LBD patients were more impaired than AD in terms
of the core LBD symptoms of Parkinsonism, cognitive
fluctuations, and visual hallucinations. The percentage of
patients taking cholinesterase inhibitors was similar in
Fig. 1 Nucleus basalis of Meynert mask. Region of interest mask for the NBM in MNI space, estimated from the SPM Anatomy Toolbox
Table 1 Demographic and clinical variables, mean (standard deviation)
HC (N = 40) AD (N = 21) LBD (N = 41) Group differences
Male to female 25:15 14:7 35:6 χ2 = 5.8, p = 0.06a
Age 73.4 (6.6) 74.7 (7.2) 74.6 (6.5) F(2, 99) = 0.4, p = 0.66b
AChEI – 20 35 χ2 = 1.4, p = 0.25c
PD meds – 0 28 χ2 = 26.2, p < 0.001c
Duration – 4.1 (2.4)f 3.2 (2.1)g U = 270, p = 0.07d
MMSE 28.8 (1.1) 21.6 (3.7) 23.1 (3.8) t60 = 1.5, p = 0.15
e
UPDRS III 3.9 (4.2) 1.7 (1.5) 20.2 (8.6) t60 = 9.7, p < 0.001
e
CAF total – 0.3 (0.7)h 5.2 (4.3)j t56 = 5.1, p < 0.001
e
Mayo total – 9.4 (4.4)h 14.3 (5.5)j t56 = 3.5, p = 0.001
e
Mayo cogn – 2.0 (1.9)h 3.0 (1.8)j t56 = 2.0, p = 0.05
e
NPI total – 7.4 (7.2)h 14.5 (10.5)g t58 = 2.7, p = 0.009
e
NPI hall – 0.05 (0.2)h 2.0 (2.0)g t58 = 4.5, p < 0.001
e
AChEI number of patients taking acetylcholinesterase inhibitors, AD Alzheimer’s disease, CAF total Clinician Assessment of Fluctuation total score, Duration
duration of cognitive symptoms in years, HC healthy controls, LBD Lewy body dementia, Mayo total Mayo Fluctuation Scale, Mayo cognitive Mayo Fluctuation
cognitive subscale, MMSE Mini-Mental State Examination, PD meds number of patients taking dopaminergic medication for the management of Parkinson’s
disease symptoms, UPDRS III Unified Parkinson’s Disease Rating Scale III (motor subsection), NPI Neuropsychiatric Inventory, NPI hall NPI hallucination subscore
aChi-square test HC, AD, LBD
bOne-way ANOVA HC, AD, LBD
cChi-square test AD, LBD
dMann-Whitney U test AD, LBD
eStudent’s t test AD, LBD
fN = 19
gN = 40
hN = 20
jN = 38
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both dementia groups whereas the majority of LBD
patients were taking dopaminergic medication compared
to none of the AD patients.
When considering only the participants that were in-
cluded in the combined EEG-MRI analysis, all groups
were still matched for age and gender, and the dementia
groups were matched for overall cognition (Supplemen-
tary Table S1).
The DLB and PDD subgroups were comparable in age,
gender, overall cognition, dementia duration, the
percentage of patients taking cholinesterase inhibitors,
cognitive fluctuations, and visual hallucinations
(Supplementary Table S2). More PDD patients were
taking dopaminergic medication compared to DLB, the
levodopa equivalent daily dose (LEDD) was higher in PDD
compared to DLB, and they had worse Parkinsonism and
total NPI symptom scores.
Alpha reactivity
Individual alpha peak frequency was significantly lower
in both dementia groups compared to controls with no
significant difference between LBD and AD (Table 2).
Alpha reactivity was reduced in both dementia groups
compared to controls and was significantly more re-
duced in LBD compared to AD (Table 2 and Fig. 3a).
Eyes-closed alpha power was reduced in AD compared
to controls, but there were no significant differences be-
tween LBD and controls or between AD and LBD. In
contrast, eyes-open alpha power (taking into account
individual alpha peak frequencies) was significantly
increased in LBD compared to both controls and AD
while there was no significant difference between AD
and controls (Fig. 2b).
There were no significant differences between the DLB
and PDD subgroups in terms of individual alpha peak
frequency, alpha reactivity, or eyes-closed and eyes-open
alpha power (see Supplementary Table S3).
There was a significant positive correlation between
individual alpha peak frequency and alpha reactivity in
the AD group (ρ = 0.77, p < 0.001), but no significant
correlations in DLB (ρ = 0.37, p = 0.08), PDD (ρ = 0.33,
p = 0.19), or controls (ρ = 0.12, p = 0.46).
The results with respect to alpha reactivity did not
change when considering the standard alpha frequency
Table 2 Group comparison of EEG characteristics and NBM volume
HC AD LBD Group comparison
Individual alpha peak 8.8 [8.4, 9.2] 7.4 [6.3, 8.4] 6.4 [6.1, 6.7] F2 = 42.1, p < 0.001
a
p (HC, AD) = 0.004
p (HC, LBD) < 0.001
p (AD, LBD) = 0.092
Alpha reactivity 0.56 [0.50, 0.63] 0.24 [0.12, 0.34] 0.08 [0.03, 0.14] F2 = 59.9, p < 0.001
b
p (HC, AD) < 0.001
p (HC, LBD) < 0.001
p (AD, LBD) = 0.014
Eyes-closed alpha power 49.1 [41.9, 56.3] 34.4 [27.5, 41.3] 39.7 [35.8, 43.5] F2 = 7.9, p = 0.019
a
p (HC, AD) = 0.018
p (HC, LBD) = 0.25
p (AD, LBD) = 0.56
Eyes-open alpha power 18.9 [16.1, 21.7] 24.2 [19.4, 29.0] 36.7 [32.4, 41.1] F2 = 35.5, p < 0.001
a
p (HC, AD) = 0.25
p (HC, LBD) < 0.001
p (AD, LBD) = 0.005
NBM volume 0.19 [0.18, 0.20] 0.17 [0.16, 0.17] 0.16 [0.15, 0.17] F2 = 13.3, p < 0.001
b
p (HC, AD) = 0.003
p (HC, LBD) < 0.001
p (AD, LBD) = 1.0
Mean [95% confidence interval]. Alpha power and alpha reactivity estimated from electrodes O1, Oz, and O2 using individual alpha peak frequencies. NBM
volume normalised to total intracranial volume. Group differences assessed by univariate ANOVA or Kruskal-Wallis ANOVA with post hoc tests corrected for
multiple comparisons
AD Alzheimer’s disease, HC healthy controls, LBD Lewy body dementia, NBM nucleus basalis of Meynert
aKruskal-Wallis ANOVA
bUnivariate ANOVA
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band from 8 to 12 Hz instead of individual alpha peak
frequencies (see Section 3 of the Supplementary
Material).
Results from all group comparisons did not change
when including gender as a covariate (see Supplementary
Table S5).
Fig. 2 Alpha reactivity analysis. a Occipital EEG signals of example control and DLB participants in eyes-closed (blue) and eyes-open (red)
conditions. b Comparison of mean power spectra for eyes-closed and eyes-open conditions for the different clinical groups. Shaded areas
indicate standard errors. AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; HC, healthy controls; PDD, Parkinson’s disease dementia
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NBM volume
Normalised NBM volume was decreased in the AD and
LBD groups compared to controls; however, there was
no significant difference between the dementia groups
(see Table 2 and Fig. 3b). There was no difference in
normalised NBM volume between the DLB and PDD
subgroups (see Supplementary Table S3).
Mean (standard deviation) of total intracranial vol-
umes in litres were 1.44 (0.11) in the control group,
1.42 (0.13) in the AD group, and 1.54 (0.15) in the
LBD group.
Association between alpha reactivity and NBM volume
When considering the whole group (across AD, LBD,
and controls), there was a significant positive correlation
between alpha reactivity and NBM volume (ρ = 0.42,
pFDR = 0.0001, Fig. 4). When considering each group sep-
arately, there was a significant positive correlation in the
PDD group (ρ = 0.66, pFDR = 0.01), whereas there were
no significant correlations in the other three groups (all
p > 0.1).
Correlations between alpha reactivity and NBM
volume were similar when using the standard alpha fre-
quency band (Section 3 of the Supplementary Material).
Correlations with clinical scores
In PDD, alpha reactivity was positively correlated with
MMSE (ρ = 0.51, p = 0.035). However, this correlation
did not survive correction for multiple comparisons. All
other correlations between alpha reactivity and NBM
volumes and clinical scores were not significant (all
p > 0.1).
Effect of dopaminergic medication in the LBD group
There were no significant differences between LBD
patients who were taking dopaminergic medication
compared to those not taking these medications
(Supplementary Table S6). Furthermore, in those
patients who were taking dopaminergic medication,
there were no significant correlations between any EEG
measures and LEDD (Supplementary Table S6).
Discussion
In this study, we investigated EEG alpha reactivity in pa-
tients with LBD compared to AD and healthy controls
and its relation to cholinergic system integrity as mea-
sured by NBM volume. We found a reduction in alpha
reactivity in the dementia groups compared to controls
which is in line with previous EEG studies in AD [19,
20] and MEG studies in DLB [21] and PDD [22]. Im-
portantly, for the first time, we also showed that alpha
reactivity is more severely affected in DLB and PDD
compared to AD. Furthermore, in agreement with pre-
vious findings in healthy participants [17, 18], we found
evidence for an involvement of the cholinergic system in
modulating alpha reactivity, specifically in PDD patients.
Since alpha reactivity is determined by the difference
between eyes-closed and eyes-open alpha power, a
Fig. 3 Group comparison. a Group comparison of alpha reactivity. b Group comparison of NBM volumes (normalised with respect to total
intracranial volume). In each boxplot, the central line corresponds to the sample median; the upper and lower borders of the box represent the
25th and 75th percentile, respectively; and the length of the whiskers is 1.5 times the interquartile range. Corresponding results from statistical
comparisons between the groups are presented in Table 2. AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; HC, healthy controls; NBM,
nucleus basalis of Meynert; PDD, Parkinson’s disease dementia
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reduction in alpha reactivity as observed in the dementia
groups can occur in two different ways (see Fig. 5). In
AD, eyes-closed alpha power was reduced compared to
controls while eyes-open alpha power was not signifi-
cantly different from healthy control levels. In the LBD
group, the opposite was the case: while eyes-closed alpha
power was not significantly reduced compared to con-
trols, eyes-open alpha power was significantly increased
compared to controls and AD (after taking into account
individual alpha peak frequencies). Furthermore, in AD,
there was a strong positive correlation between alpha
reactivity and individual alpha peak frequency, indicating
that the reduction in alpha reactivity in this group might
be more related to general alpha power reduction and
alpha slowing [26]. In contrast, in LBD, even though the
general EEG slowing was slightly more severe than in
AD, there was no significant correlation between alpha
reactivity and alpha slowing, indicating that the loss of
alpha reactivity might be a process that is more inde-
pendent from general EEG slowing than in AD. Instead,
Fig. 4 Correlations between alpha reactivity and NBM volume. Spearman’s correlations between alpha reactivity and normalised NBM volume
across all groups and in each group separately. p values are FDR (false discovery rate)-corrected for multiple comparisons. AD, Alzheimer’s disease;
DLB, dementia with Lewy bodies; FDR, false discovery rate; HC, healthy controls; NBM, nucleus basalis of Meynert; PDD, Parkinson’s
disease dementia
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loss of alpha reactivity in LBD might be more related to
a lack of neuronal desynchronization upon opening the
eyes.
In the healthy human brain, opening of the eyes nor-
mally leads to a suppression of alpha power due to neur-
onal desynchronization [15, 16]. This state of low alpha
power has been associated with highest levels of cortical
responsiveness and has been suggested to be a more
externally oriented brain state in which it is easiest for
external stimuli to reach the cortex [33]. In contrast,
higher eyes-open alpha power indicates a more intern-
ally oriented state making it harder for external stimuli
to be perceived [33]. Evidence comes from studies of
pre-stimulus alpha power which showed that perform-
ance is highest if pre-stimulus alpha power is low [34].
However, the extent of alpha power suppression is not
only important for processing of visual stimuli, but has
also been related to attention and cognitive performance
more generally. Low alpha power has been associated
with higher activity in attention networks [35]. Further-
more, the extent of alpha suppression upon eyes opening
has been shown to be positively correlated with cognitive
performance [36] and has been related to attention and
cognitive load [37]. Simultaneous EEG-fMRI studies
have reported a negative relationship between blood
oxygen level dependent (BOLD) signal and alpha power
indicating a simultaneous occurrence of occipital alpha
power decrease and neuronal activation in the occipital
cortex and other cortical areas [38, 39].
The increase in eyes-open alpha power in LBD might
therefore indicate a specific impairment in neuronal
desynchronization. Instead of activating neurons in
primary and secondary visual areas when opening the
eyes, the cortex of LBD patients seems to stay in a more
synchronised state which might lead to a loss of cortical
responsiveness. This in turn might lead to problems with
attention and cognition [36, 37].
Several previous studies have investigated the mecha-
nisms that lead to neuronal desynchronization when
opening the eyes and thereby modulate alpha reactivity.
There is compelling evidence for a role of the choliner-
gic system [17, 18]. The suppression of alpha power
from eyes closed to eyes open has been shown to be re-
lated to an increase in functional connectivity between
the NBM and primary visual areas [17]. Furthermore,
white matter integrity along fibre tracts connecting the
NBM with occipital areas was negatively correlated with
alpha reactivity. These findings suggest that cholinergic
drive from the NBM might play an important role in
modulating the reduction in alpha power from eyes
Fig. 5 Interpretation of alpha reactivity changes. Illustration of how a reduction in alpha reactivity can be mainly due to a decrease in eyes-closed
alpha power (in AD) or an increase in eyes-open alpha power (in LBD) compared to controls. AD, Alzheimer’s disease; LBD, Lewy body dementia;
HC, healthy controls
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closed to eyes open [17]. Additionally, Osipova et al.
[18] showed that alpha power suppression upon opening
the eyes was impaired when cholinergic neurotransmis-
sion was temporarily blocked by the cholinergic anta-
gonist scopolamine, further suggesting that the integrity
of the cholinergic system is crucial for alpha power
suppression.
In the present study, across all groups and in the PDD
group in particular, loss of alpha reactivity was related to
volume loss within the NBM. The failure to activate
neural sources in occipital cortex upon opening the eyes
might therefore be due to a loss of cholinergic drive
from the NBM which is in line with these previous stud-
ies [17, 18]. The lack of a specific association between
alpha reactivity and NBM volume in DLB might be due
to the fact that functional impairment within the cholin-
ergic system can precede structural abnormalities; in
particular, it has been shown that even prior to neurode-
generation, alpha-synuclein can reduce cholinergic
neurotransmitter production [9]. In contrast, PDD pa-
tients with a comparable level of cognitive impairment
typically have a longer disease duration which might lead
to structural abnormalities within the cholinergic system
playing a greater role in the loss of alpha reactivity in
these patients. Furthermore, PDD patients show less AD
co-pathology than patients with DLB [40], making PDD
a “purer” alpha-synucleinopathy which might explain the
discrepant findings in these two groups.
The observed association between alpha reactivity and
the cholinergic system—if replicated in other studies—
might suggest alpha reactivity as an interesting potential
measure of treatment response in clinical trials which
seek to remediate cholinergic function.
Contrary to our hypothesis, alpha reactivity was not
significantly correlated with measures of cognitive fluc-
tuation severity in LBD. This might be due to the fact
that alpha reactivity was quite severely reduced in most
patients and most of them had cognitive fluctuations,
which might have led to a floor effect. The fact that AD
patients, who have less severe cognitive fluctuations
compared to LBD [25], showed a less severe reduction
in alpha reactivity might indicate that loss of alpha re-
activity is related to the presence of cognitive fluctua-
tions, while a relationship between alpha reactivity and
cognitive fluctuation severity is more difficult to estab-
lish based on the present results.
We decided to use individual alpha peak frequencies
to determine alpha power instead of using a fixed alpha
frequency band (usually from 8 to 12 Hz) [21, 22]. This
was done to account for a shift of the alpha peak to
slower frequencies in AD and LBD [26, 27]. The mean
alpha peak in the LBD group therefore lies within a fre-
quency range that has been termed pre-alpha [41, 42],
but is also considered to represent the fast-theta band in
other studies [27]. However, we showed that alpha re-
activity differences between groups and the association
with NBM volume remained the same when repeating
the analysis using the standard alpha frequency band.
A potential limitation of the present study is the fact
that most dementia patients were taking cholinesterase
inhibitors which have been shown to influence the cor-
tical EEG signal by increasing eyes-closed alpha power
and reducing slow-wave activity [43–45]. Due to the low
number of patients not taking these medications, it was
not possible to study the effect of cholinesterase inhibi-
tors on the present results nor would it be ethical to
withdraw these medications. However, investigating the
effect of cholinergic medication on alpha reactivity in
AD and LBD will be an important step of future re-
search which will also help to better understand the
relationship between alpha reactivity and cholinergic
neurotransmission and evaluate the potential use of
alpha reactivity as a predictor of treatment response.
A further potential limitation is the use of dopamin-
ergic medication in many LBD patients which has also
been shown to influence EEG signals by increasing eyes-
closed alpha power [46, 47]. However, we did not find
differences between LBD patients who were taking dopa-
minergic medication compared to those patients not
taking these medications, and there were no significant
correlations between LEDD and the EEG measures
included in the present study.
Conclusions
In conclusion, we showed that LBD patients show an
impairment in neuronal desynchronization upon open-
ing the eyes which distinguishes these patients from
healthy controls and patients with AD and which might
be related to a loss of cholinergic drive from the NBM
in PDD. While the importance of a general slowing of
the EEG signal in LBD has been discussed in many stud-
ies [26, 27], changes in eyes-open resting EEG in these
patients have not been investigated in detail. The present
study therefore complements previous research by
showing that studying eyes-open EEG data can
provide important new insights into changes in brain
state in LBD.
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